Dependence of Castration-Resistant Prostate Cancer (CRPC) Stem Cells on CRPC-Associated Fibroblasts

被引:21
作者
Adisetiyo, Helty [1 ,2 ]
Liang, Mengmeng [3 ]
Liao, Chun-Peng [4 ]
Jeong, Joseph H. [5 ]
Cohen, Michael B. [6 ]
Roy-Burman, Pradip [1 ,3 ]
Frenkel, Baruch [1 ,2 ,7 ]
机构
[1] Univ So Calif, Los Angeles, CA 90033 USA
[2] Univ So Calif, Inst Med Genet, Los Angeles, CA 90033 USA
[3] Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA
[4] Univ So Calif, Keck Sch Med, Ctr Appl Mol Med, Los Angeles, CA 90033 USA
[5] Med Coll Wisconsin, Dept Dermatol, Milwaukee, WI 53226 USA
[6] Univ Utah, Dept Pathol, Salt Lake City, UT USA
[7] Univ So Calif, Dept Orthopaed Surg, Los Angeles, CA 90033 USA
基金
美国国家卫生研究院;
关键词
RB DEFICIENCY; IN-VITRO; TUMORIGENESIS; THERAPY; MODELS; NICHE; P53;
D O I
10.1002/jcp.24546
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We previously established a role for cancer-associated fibroblasts (CAF) in enhancing the self-renewal and differentiation potentials of putative prostate cancer stem cells (CSC). Our published work focused on androgen-dependent prostate cancer (ADPC) using the conditional Pten deletion mouse model. Employing the same model, we now describe the interaction of CAF and CSC in castration-resistant prostate cancer (CRPC). CAF isolated from ADPC (ADPCAF) and from CRPC (CRPCAF) were compared in terms of their ability to support organoid formation and tumor initiation by CSC from CRPC (CRPCSC) in vitro and in vivo. CRPCSC formed spheroids in vitro and well-differentiated glandular structures under the renal capsules of recipient mice in vivo more effectively in the presence of CRPCAF compared to ADPCAF. Furthermore, whereas CSC with CAF from ADPC formed mostly well-differentiated tumors in our previous study, we now show that CRPCSC, when combined with CRPCAF (but not ADPCAF), can form aggressive, poorly-differentiated tumors. The potential of CRPCAF to support organoid/tumor formation by CRPCSC remained greater even when compared to 10-fold more ADPCAF, suggesting that paracrine factors produced specifically by CRPCAF preferentially potentiate the stemness and tumorigenic properties of the corresponding CSC. This apparently unique property of CRPCAF was notable when the CAF and CSC were grafted in either intact or castrated recipient mice. In both environments, CRPCAF induced in the epithelial compartment higher proliferative activity compared to ADPCAF, indicated by a higher Ki67 index. Factors released by CRPCAF to regulate CRPCSC may be targeted to develop novel therapeutic approaches to manage advanced prostate cancer. J. Cell. Physiol. 229: 1170-1176, 2014. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:1170 / 1176
页数:7
相关论文
共 26 条
  • [1] Loss of Survivin in the Prostate Epithelium Impedes Carcinogenesis in a Mouse Model of Prostate Adenocarcinoma
    Adisetiyo, Helty
    Liang, Mengmeng
    Liao, Chun-Peng
    Aycock-Williams, Ari
    Cohen, Michael B.
    Xu, Shili
    Neamati, Nouri
    Conway, Edward M.
    Cheng, Chieh-Yang
    Nikitin, Alexander Yu.
    Roy-Burman, Pradip
    [J]. PLOS ONE, 2013, 8 (07):
  • [2] A perivascular niche for brain tumor stem cells
    Calabrese, Christopher
    Poppleton, Helen
    Kocak, Mehmet
    Hogg, Twala L.
    Fuller, Christine
    Hamner, Blair
    Oh, Eun Young
    Gaber, M. Waleed
    Finklestein, David
    Allen, Meredith
    Frank, Adrian
    Bayazitov, Ildar T.
    Zakharenko, Stanislav S.
    Gajjar, Amar
    Davidoff, Andrew
    Gilbertson, Richard J.
    [J]. CANCER CELL, 2007, 11 (01) : 69 - 82
  • [3] A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer
    Clark, Ashlee K.
    Taubenberger, Anna V.
    Taylor, Renea A.
    Niranjan, Birunthi
    Chea, Zhen Y.
    Zotenko, Elena
    Sieh, Shirly
    Pedersen, John S.
    Norden, Sam
    Frydenberg, Mark
    Grummet, Jeremy P.
    Pook, David W.
    Stirzaker, Clare
    Clark, Susan J.
    Lawrence, Mitchell G.
    Ellem, Stuart J.
    Hutmacher, Dietmar W.
    Risbridger, Gail P.
    [J]. BIOMATERIALS, 2013, 34 (20) : 4777 - 4785
  • [4] Prostate cancer stem cells
    Collins, Anne T.
    Maitland, Norman J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (09) : 1213 - 1218
  • [5] Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
    Dayyani, Farshid
    Gallick, Gary E.
    Logothetis, Christopher J.
    Corn, Paul G.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22): : 1665 - 1675
  • [6] Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group
    Grimm, Peter
    Billiet, Ignace
    Bostwick, David
    Dicker, Adam P.
    Frank, Steven
    Immerzeel, Jos
    Keyes, Mira
    Kupelian, Patrick
    Lee, W. Robert
    Machtens, Stefan
    Mayadev, Jyoti
    Moran, Brian J.
    Merrick, Gregory
    Millar, Jeremy
    Roach, Mack
    Stock, Richard
    Shinohara, Katsuto
    Scholz, Mark
    Weber, Ed
    Zietman, Anthony
    Zelefsky, Michael
    Wong, Jason
    Wentworth, Stacy
    Vera, Robyn
    Langley, Stephen
    [J]. BJU INTERNATIONAL, 2012, 109 : 22 - 29
  • [7] Lang SH, 2001, CELL GROWTH DIFFER, V12, P631
  • [8] Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence
    Liao, Chun-Peng
    Zhong, Chen
    Saribekyan, Gohar
    Bading, James
    Park, Ryan
    Conti, Peter S.
    Moats, Rex
    Berns, Anton
    Shi, Wei
    Zhou, Zongxiang
    Nikitin, Alexander Yu
    Roy-Burman, Pradip
    [J]. CANCER RESEARCH, 2007, 67 (15) : 7525 - 7533
  • [9] Cancer-Associated Fibroblasts Enhance the Gland-Forming Capability of Prostate Cancer Stem Cells
    Liao, Chun-Peng
    Adisetiyo, Helty
    Liang, Mengmeng
    Roy-Burman, Pradip
    [J]. CANCER RESEARCH, 2010, 70 (18) : 7294 - 7303
  • [10] Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells
    Miki, J.
    Rhim, J. S.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2008, 11 (01) : 32 - 39